The science of fibromyalgia

Mayo Clinic Proceedings

Volumn 86, Issue 9, 2011, Pages 907-911

  Clauw, Daniel J ^a   Arnold, Lesley M ^b   McCarberg, Bill H ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL;

ALLODYNIA; ANALGESIA; COGNITIVE DEFECT; DRUG APPROVAL; DRUG INDICATION; FATIGUE; FIBROMYALGIA; HUMAN; HYPERALGESIA; INDIVIDUALIZATION; MEDICAL RESEARCH; NEUROCHEMISTRY; NOCICEPTION; PAIN THRESHOLD; PATIENT CARE; REVIEW; SLEEP DISORDER;

EID: 80052200952     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2011.0206     Document Type: Review

References (23)

1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1):19-28.
2. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis Rheum. 2008;58(1):26-35.
3. Burckhardt CS, Goldenberg D, Crofford L, et al. Guidelines for the Management of Fibromyalgia Syndrome Pain in Adults and Children: APS Clinical Practice Guidelines Series, No. 4. Glenview, IL: American Pain Society; 2005.
4. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292(19):2388-2395. (Pubitemid 39491924)
5. Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008;73(1):114-120.
6. Goldenberg DL, Schaefer CR, Ryan K, Chandran A, Slateva G. What is the true cost of fibromyalgia to our society: results from a cross-sectional survey in the United States. Paper presented at: American College of Rheumatology. Philadelphia, PA: October 18, 2009.
7. Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract. 2007;61(9):1498-1508. (Pubitemid 47228612)
8. Russell IJ, Larson AA. Neurophysiopathogenesis of fibromyalgia syndrome: a unified hypothesis. Rheum Dis Clin North Am. 2009;35(2):421-435.
9. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46(5):1333-1343. (Pubitemid 34525843)
10. Nebel MB, Gracely RH. Neuroimaging of fibromyalgia. Rheum Dis Clin North Am. 2009;35(2):313-327.
11. Williams DA, Clauw DJ. Understanding fibromyalgia: lessons from the broader pain research community. J Pain. 2009;10(8):777-791.
12. Staud R. Abnormal pain modulation in patients with spatially distributed chronic pain: fibromyalgia. Rheum Dis Clin North Am. 2009;35(2):263-274.
13. Ablin K, Clauw DJ. From fibrositis to functional somatic syndromes to a bell-shaped curve of pain and sensory sensitivity: evolution of a clinical construct. Rheum Dis Clin North Am. 2009;35(2):233-251.
14. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of a multicenter criteria committee. Arthritis Rheum. 1990;33(2):160-172. (Pubitemid 20098653)
15. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62(5):600-610.
16. Affaitati G, Costantini R, Fabrizio A, Lapenna D, Tafuri E, Giamberardino MA. Effects of treatment of peripheral pain generators in fibromyalgia patients. Eur J Pain. 2011;15(1):61-69.
17. Marques AP, Ferreira EA, Matsutani LA, Pereira CA, Assumpção A. Quantifying pain threshold and quality of life of fibromyalgia patients. Clin Rheumatol. 2005;24(3):266-271. (Pubitemid 40872225)
18. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35(5):550-556.
19. Baraniuk JN, Whalen G, Cunningham J, Clauw DJ. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord. 2004;5:48.
20. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci. 2007;27(37):10000-10006. (Pubitemid 47404015)
21. Arnold LM. The pathophysiology, diagnosis, and treatment of fibromyalgia. Psychiatr Clin North Am. 2010;33(2):375-408.
22. May A. Chronic pain may change the structure of the brain. Pain. 2008;137(1):7-15.
23. DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain. 2001;90(1-2):1-6. (Pubitemid 32146552)